Aliases & Classifications for Opioid Addiction

MalaCards integrated aliases for Opioid Addiction:

Name: Opioid Addiction 25
Opiate Addiction 25 73
Opiate Dependence 25
Opioid Dependence 25

Summaries for Opioid Addiction

Genetics Home Reference : 25 Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. Some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. Commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. Some other opioids, such as heroin, are illegal drugs of abuse.

MalaCards based summary : Opioid Addiction, also known as opiate addiction, is related to opiate dependence and heroin dependence. An important gene associated with Opioid Addiction is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Circadian entrainment. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Related Diseases for Opioid Addiction

Diseases related to Opioid Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 33.9 DRD2 OPRD1 OPRK1 OPRM1
2 heroin dependence 32.1 DRD2 OPRD1 OPRM1
3 morphine dependence 31.6 CCK OPRD1 OPRK1 OPRM1
4 chronic pain 30.1 COMT OPRM1
5 cocaine dependence 29.9 DRD2 OPRD1 OPRK1 OPRM1
6 alcohol dependence 27.0 CCK COMT DRD2 GRIN2A OPRD1 OPRK1
7 opioid dependence 1 12.2
8 schizophreniform disorder 10.5 COMT DRD2
9 polysubstance abuse 10.4 COMT DRD2
10 paralytic ileus 10.4 ABCB1 CCK
11 tobacco addiction 10.3 COMT DRD2 OPRM1
12 gastroparesis 10.2 ABCB1 CCK DRD2
13 drug dependence 10.2 DRD2 OPRD1 OPRK1 OPRM1
14 eating disorder 10.2 CCK COMT DRD2
15 substance dependence 10.2 DRD2 OPRD1 OPRK1 OPRM1
16 depression 10.0
17 tardive dyskinesia 10.0 COMT DRD2
18 aging 9.9
19 autism 9.8
20 fibromyalgia 9.8
21 paine syndrome 9.8
22 headache 9.8
23 pulmonary disease, chronic obstructive 9.8
24 withdrawal disorder 9.8
25 borderline personality disorder 9.8
26 personality disorder 9.8
27 complex regional pain syndrome 9.8
28 neuronitis 9.8
29 cluster headache 9.8
30 anxiety 9.8 CCK CCKBR COMT
31 pain agnosia 9.7 CCK OPRK1 OPRM1 PNOC
32 agnosia 9.7 CCK OPRK1 OPRM1 PNOC
33 attention deficit-hyperactivity disorder 9.7 COMT DRD2 GRIN2A OPRM1
34 neonatal abstinence syndrome 9.7 COMT CYP2B6 OPRD1 OPRK1 OPRM1
35 specific developmental disorder 9.6 CCK COMT OPRM1 PNOC
36 disease of mental health 9.4 CCK COMT DRD2 GRIN2A OPRM1
37 panic disorder 9.2 CCK CCKAR CCKBR COMT
38 opioid abuse 8.7 CCK CCKAR CCKBR DRD2 GRIN3B OPRM1
39 schizophrenia 8.4 CCK CCKAR COMT DRD2 GRIN2A GRIN3B
40 pancreatic cancer 8.3 CCK CCKAR CCKBR MAPK1 MAPK3

Comorbidity relations with Opioid Addiction via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Major Depressive Disorder Osteoporosis

Graphical network of the top 20 diseases related to Opioid Addiction:



Diseases related to Opioid Addiction

Symptoms & Phenotypes for Opioid Addiction

MGI Mouse Phenotypes related to Opioid Addiction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 ABCB1 CCK CCKAR CCKBR COMT DRD2
2 endocrine/exocrine gland MP:0005379 9.96 ABCB1 CCK CCKAR CCKBR COMT DRD2
3 homeostasis/metabolism MP:0005376 9.93 ABCB1 CCK CCKAR CCKBR COMT DRD2
4 digestive/alimentary MP:0005381 9.92 MAPK1 MAPK3 OPRK1 OPRM1 ABCB1 CCKAR
5 integument MP:0010771 9.65 CCKBR DRD2 GRIN2A GRIN2D MAPK1 MAPK3
6 nervous system MP:0003631 9.44 MAPK1 MAPK3 OPRD1 OPRK1 OPRM1 ABCB1

Drugs & Therapeutics for Opioid Addiction

Drugs for Opioid Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
4
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
5
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
6
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
8
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
10
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
11
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
12
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
13
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
14
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
15
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
16
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-42-6 5284603
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
18
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
19
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Not Applicable 56-12-2 119
20
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
21
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
22
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
23
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
24
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
25
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
26 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
27 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Adjuvants, Anesthesia Phase 4,Phase 1,Not Applicable
31 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Nicotinic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 459)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
4 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
5 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
6 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
7 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
8 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
9 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
10 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
11 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
12 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
14 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
15 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
16 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
17 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
18 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
19 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
20 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
21 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
22 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
23 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
24 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
25 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
26 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
27 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
28 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
29 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
30 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
31 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
32 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
33 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
34 A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
35 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
36 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
37 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
38 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
39 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
40 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
41 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
42 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
43 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
44 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Active, not recruiting NCT02741076 Phase 4 Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER
45 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
46 Liposomal Bupivacaine in Ambulatory Hand Surgery Enrolling by invitation NCT02933814 Phase 4 Liposomal Bupivicaine
47 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
48 Gabapentin Regimens and Their Effects on Opioid Consumption Not yet recruiting NCT03334903 Phase 4 Gabapentin
49 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
50 Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone

Search NIH Clinical Center for Opioid Addiction

Genetic Tests for Opioid Addiction

Anatomical Context for Opioid Addiction

MalaCards organs/tissues related to Opioid Addiction:

41
Brain, Testes, Liver, Bone, Skin, Cortex, Prefrontal Cortex

Publications for Opioid Addiction

Articles related to Opioid Addiction:

(show top 50) (show all 94)
# Title Authors Year
1
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. ( 28862903 )
2018
2
Medication development in opioid addiction: Meaningful clinical end points. ( 29593105 )
2018
3
Opioid Addiction in Pregnancy: Does Depression Negatively Impact Adherence With Prenatal Care? ( 29068826 )
2018
4
Curbing opioid addiction needs more than new drugs. ( 29921860 )
2018
5
The Neurobiology of Opioid Addiction and the Potential for Prevention Strategies. ( 29710202 )
2018
6
Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. ( 29210332 )
2018
7
Intolerance of uncertainty and conditioned place preference in opioid addiction. ( 29844956 )
2018
8
Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis. ( 29553937 )
2018
9
Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. ( 29676241 )
2018
10
Home-based delivery of XR-NTX in youth with opioid addiction. ( 28867062 )
2018
11
Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue. ( 29220615 )
2018
12
Opioid addiction, diversion, and abuse in chronic and cancer pain. ( 29465470 )
2018
13
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
14
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction. ( 29441714 )
2018
15
Association of the Five-Factor Model personality traits and opioid addiction treatment outcome. ( 28953780 )
2017
16
Opioid Addiction and Implications for Employers. ( 29465184 )
2017
17
Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction. ( 28801372 )
2017
18
Battling the biology of opioid addiction. ( 28697181 )
2017
19
Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. ( 29266577 )
2017
20
Support for Treating Opioid Addiction With Medication. ( 29209706 )
2017
21
Special indications for Opioid Free Anaesthesia and Analgesia, patient and procedure related: Including obesity, sleep apnoea, chronic obstructive pulmonary disease, complex regional pain syndromes, opioid addiction and cancer surgery. ( 29739543 )
2017
22
Contingency management for tobacco smoking during opioid addiction treatment: a randomised pilot study. ( 28864706 )
2017
23
Five sentence letter from 1980 helped create US opioid addiction crisis, study concludes. ( 28588040 )
2017
24
Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption. ( 28607934 )
2017
25
Managing Opioid Addiction Risk in Plastic Surgery during the Perioperative Period. ( 28953743 )
2017
26
Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic. ( 29049522 )
2017
27
The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients Undergoing Maintenance Treatment for Opioid Addiction in Sabzevar Parish in 2017. ( 29359178 )
2017
28
Opioid, Addiction ( 28846246 )
2017
29
How inappropriate prescribing prompted the opioid addiction ravaging small town America. ( 29051156 )
2017
30
Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. ( 26876472 )
2016
31
Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. ( 27240623 )
2016
32
ADHD risk alleles associated with opiate addiction: study of addicted parents and their children. ( 27064247 )
2016
33
The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. ( 27061230 )
2016
34
Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. ( 26044620 )
2015
35
Association between the traditional Chinese medicine pathological factors of opioid addiction and DRD2/ANKK1 TaqIA polymorphisms. ( 26138154 )
2015
36
Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system. ( 25336035 )
2014
37
Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [CaA^a8_]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. ( 25760046 )
2014
38
Role of Methadone in Induction and/or Exacerbation of Cluster Headache in Patients Treated for Opioid Addiction. ( 25487851 )
2014
39
The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. ( 24359476 )
2014
40
Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. ( 24231353 )
2013
41
NCK2 is significantly associated with opiates addiction in African-origin men. ( 23533358 )
2013
42
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. ( 23480249 )
2013
43
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. ( 21790905 )
2013
44
Case-control association analysis of polymorphisms in the I'-opioid receptor, OPRD1, with cocaine and opioid addicted populations. ( 22795689 )
2013
45
Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction. ( 23988166 )
2013
46
High-sensitivity CRP in opiate addiction: relative and age-dependent elevations. ( 22297435 )
2012
47
Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. ( 21724673 )
2011
48
Elevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts. ( 21957825 )
2011
49
Comparison of childhood sexual histories in subjects with pedophilia or opiate addiction and healthy controls: is childhood sexual abuse a risk factor for addictions? ( 21107144 )
2010
50
Investigating the relationship between sexual and chemical addictions by comparing executive function in subjects with pedophilia or opiate addiction and healthy controls. ( 21107145 )
2010

Variations for Opioid Addiction

Expression for Opioid Addiction

Search GEO for disease gene expression data for Opioid Addiction.

Pathways for Opioid Addiction

Pathways related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CCK CCKAR CCKBR DRD2 GRIN2A GRIN2D
2
Show member pathways
12.63 COMT DRD2 GRIN2A GRIN2D GRIN3B MAPK1
3
Show member pathways
12.63 CCK CCKAR CCKBR DRD2 GRIN2A GRIN2D
4
Show member pathways
12.24 CCK CCKBR MAPK1 MAPK3
5 12.15 DRD2 GRIN2A GRIN2D GRIN3B
6
Show member pathways
12.03 CCKAR CCKBR GRIN2A GRIN2D
7
Show member pathways
11.87 DRD2 GRIN2A GRIN2D MAPK1 MAPK3
8 11.85 MAPK1 MAPK3 OPRD1
9
Show member pathways
11.82 GRIN2A GRIN2D GRIN3B
10
Show member pathways
11.74 DRD2 GRIN2A GRIN2D GRIN3B
11
Show member pathways
11.74 DRD2 GRIN2A GRIN2D GRIN3B MAPK1 MAPK3
12 11.64 DRD2 MAPK1 MAPK3
13
Show member pathways
11.58 ABCB1 COMT CYP2B6
14 11.49 GRIN2A GRIN2D MAPK1 MAPK3
15
Show member pathways
11.4 ABCB1 COMT CYP2B6
16 11.18 GRIN2A GRIN2D GRIN3B
17 10.93 MAPK1 MAPK3
18 10.91 MAPK1 MAPK3
19 10.9 MAPK1 MAPK3
20 10.87 MAPK1 MAPK3
21 10.87 MAPK1 MAPK3
22 10.86 MAPK1 MAPK3
23 10.82 MAPK1 MAPK3
24 10.75 MAPK1 MAPK3
25 10.67 MAPK1 MAPK3
26 10.66 CCK CCKBR
27 10.62 MAPK1 MAPK3

GO Terms for Opioid Addiction

Cellular components related to Opioid Addiction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.8 CCK COMT DRD2 MAPK1 OPRM1
2 dendrite GO:0030425 9.8 CCK COMT DRD2 OPRK1 OPRM1 PNOC
3 plasma membrane GO:0005886 9.8 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
4 postsynaptic membrane GO:0045211 9.77 COMT GRIN2A GRIN2D GRIN3B OPRD1
5 pseudopodium GO:0031143 9.48 MAPK1 MAPK3
6 axon terminus GO:0043679 9.46 DRD2 OPRD1 OPRK1 PNOC
7 NMDA selective glutamate receptor complex GO:0017146 9.43 GRIN2A GRIN2D GRIN3B
8 perikaryon GO:0043204 9.02 CCK DRD2 MAPK1 OPRK1 OPRM1
9 membrane GO:0016020 10.28 ABCB1 CCKAR CCKBR COMT CYP2B6 DRD2
10 integral component of plasma membrane GO:0005887 10 CCKAR DRD2 GRIN2A GRIN2D OPRD1 OPRK1

Biological processes related to Opioid Addiction according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 ABCB1 COMT DRD2 GRIN2A
2 MAPK cascade GO:0000165 9.97 GRIN2A GRIN2D MAPK1 MAPK3
3 response to lipopolysaccharide GO:0032496 9.93 COMT MAPK1 MAPK3 OPRM1
4 calcium ion transmembrane transport GO:0070588 9.89 GRIN2A GRIN3B OPRM1
5 axonogenesis GO:0007409 9.88 CCK CCKAR DRD2
6 response to toxic substance GO:0009636 9.86 DRD2 MAPK1 MAPK3
7 response to ethanol GO:0045471 9.86 DRD2 GRIN2A OPRK1 OPRM1
8 locomotory behavior GO:0007626 9.85 DRD2 OPRK1 OPRM1
9 chemical synaptic transmission GO:0007268 9.85 GRIN2A MAPK1 OPRD1 OPRK1 OPRM1 PNOC
10 response to estrogen GO:0043627 9.83 COMT MAPK1 OPRK1
11 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 OPRD1 OPRK1 OPRM1
12 neuropeptide signaling pathway GO:0007218 9.83 OPRD1 OPRK1 OPRM1 PNOC
13 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.81 OPRD1 OPRK1 OPRM1
14 long-term synaptic potentiation GO:0060291 9.79 GRIN2A GRIN2D MAPK1
15 response to cocaine GO:0042220 9.77 DRD2 OPRK1 OPRM1
16 response to morphine GO:0043278 9.74 DRD2 OPRK1 OPRM1
17 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.71 MAPK1 MAPK3
18 face development GO:0060324 9.7 MAPK1 MAPK3
19 positive regulation of long-term synaptic potentiation GO:1900273 9.7 DRD2 GRIN2A
20 positive regulation of telomere capping GO:1904355 9.7 MAPK1 MAPK3
21 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
22 behavioral response to ethanol GO:0048149 9.69 DRD2 OPRM1
23 regulation of ossification GO:0030278 9.69 MAPK1 MAPK3
24 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.69 MAPK1 MAPK3
25 ionotropic glutamate receptor signaling pathway GO:0035235 9.69 GRIN2A GRIN2D GRIN3B
26 cellular response to dopamine GO:1903351 9.68 MAPK1 MAPK3
27 regulation of stress-activated MAPK cascade GO:0032872 9.67 MAPK1 MAPK3
28 outer ear morphogenesis GO:0042473 9.67 MAPK1 MAPK3
29 Bergmann glial cell differentiation GO:0060020 9.66 MAPK1 MAPK3
30 excitatory chemical synaptic transmission GO:0098976 9.66 GRIN2A GRIN2D
31 regulation of early endosome to late endosome transport GO:2000641 9.65 MAPK1 MAPK3
32 startle response GO:0001964 9.65 DRD2 GRIN2A GRIN2D
33 excitatory postsynaptic potential GO:0060079 9.65 DRD2 GRIN2A GRIN2D GRIN3B OPRM1
34 calcium ion transmembrane import into cytosol GO:0097553 9.64 GRIN2A GRIN2D
35 trachea formation GO:0060440 9.64 MAPK1 MAPK3
36 dopamine metabolic process GO:0042417 9.63 COMT DRD2 GRIN2A
37 caveolin-mediated endocytosis GO:0072584 9.62 MAPK1 MAPK3
38 regulation of cellular pH GO:0030641 9.62 MAPK1 MAPK3
39 eating behavior GO:0042755 9.62 CCK OPRD1 OPRK1 OPRM1
40 regulation of Golgi inheritance GO:0090170 9.61 MAPK1 MAPK3
41 sensory perception GO:0007600 9.61 OPRK1 OPRM1 PNOC
42 response to epidermal growth factor GO:0070849 9.6 MAPK1 MAPK3
43 cardiac neural crest cell development involved in heart development GO:0061308 9.58 MAPK1 MAPK3
44 opioid receptor signaling pathway GO:0038003 9.58 OPRD1 OPRK1 OPRM1
45 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.55 OPRK1 OPRM1
46 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.55 CCKAR CCKBR OPRD1 OPRK1 OPRM1
47 cholecystokinin signaling pathway GO:0038188 9.54 CCKAR CCKBR
48 sensory perception of pain GO:0019233 9.43 GRIN2A MAPK1 MAPK3 OPRD1 OPRK1 OPRM1
49 regulation of sensory perception of pain GO:0051930 9.17 CCK COMT GRIN2A GRIN2D OPRD1 OPRK1
50 signal transduction GO:0007165 10.23 CCK CCKAR CCKBR DRD2 MAPK1 OPRD1

Molecular functions related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.93 CCKAR CCKBR DRD2 OPRD1 OPRK1 OPRM1
2 obsolete signal transducer activity GO:0004871 9.8 CCKAR CCKBR DRD2 OPRD1 OPRM1
3 MAP kinase kinase activity GO:0004708 9.51 MAPK1 MAPK3
4 neuropeptide binding GO:0042923 9.5 OPRD1 OPRK1 OPRM1
5 MAP kinase activity GO:0004707 9.49 MAPK1 MAPK3
6 NMDA glutamate receptor activity GO:0004972 9.48 GRIN2A GRIN2D
7 glutamate-gated calcium ion channel activity GO:0022849 9.43 GRIN2A GRIN2D
8 ionotropic glutamate receptor activity GO:0004970 9.43 GRIN2A GRIN2D GRIN3B
9 cholecystokinin receptor activity GO:0004951 9.37 CCKAR CCKBR
10 extracellularly glutamate-gated ion channel activity GO:0005234 9.33 GRIN2A GRIN2D GRIN3B
11 peptide binding GO:0042277 9.26 CCKAR OPRD1 OPRK1 OPRM1
12 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opioid Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....